Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers-Reference-Cited by-同舟云学术

Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers

Published:2019-02-18 Issue:4 Volume:85 Page:762-770
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Gan Li‐Ming¹²³^ORCID,Lagerström‐Fermér Maria¹,Ericsson Hans¹,Nelander Karin¹,Lindstedt Eva‐Lotte⁴,Michaëlsson Erik⁴,Kjaer Magnus¹,Heijer Maria¹,Whatling Carl⁴,Fuhr Rainard⁵

Affiliation:

1. Early Clinical DevelopmentIMED Biotech Unit, AstraZeneca Gothenburg Sweden

2. Department of Molecular and Clinical Medicine, Institute of MedicineSahlgrenska Academy at the University of Gothenburg Gothenburg Sweden

3. Department of CardiologySahlgrenska University Hospital Gothenburg Sweden

4. Cardiovascular, Renal and MetabolismIMED Biotech Unit, AstraZeneca Gothenburg Sweden

5. PAREXEL Early Phase Clinical Unit Berlin Germany

Funder

AstraZeneca

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology